Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda.

ABSTRACT:

Objectives

Our objective was to compare the efficacy and safety of three drug combinations for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense.

Design

This trial was a randomized, open-label, active control, parallel clinical trial comparing three arms.

Setting

The study took place at the Sleeping Sickness Treatment Center run by Médecins Sans Frontières at Omugo, Arua District, Uganda

Participants

Stage 2 patients diagnosed in Northern Uganda were screened for inclusion and a total of 54 selected.

Interventions

Three drug combinations were given to randomly assigned patients: melarsoprol-nifurtimox (M+N), melarsoprol-eflornithine (M+E), and nifurtimox-eflornithine (N+E). Dosages were uniform: intravenous

SUBMITTER: Priotto G 

PROVIDER: S-EPMC1687208 | biostudies-literature | 2006 Dec

REPOSITORIES: biostudies-literature